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Howell et al. examine a mAb, FVM04, that
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two ZMappTM components, the antibody
cocktail retains EBOV protection similar
to that of ZMappTM and extends
protection against SUDV. Specific
glycoprotein mutations that enhance the
exposure of cross-neutralizing epitopes
are described.
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Previous efforts to identify cross-neutralizing anti-
bodies to the receptor-binding site (RBS) of ebolavi-
rus glycoproteins have been unsuccessful, largely
because the RBS is occluded on the viral surface.
We report a monoclonal antibody (FVM04) that
targets a uniquely exposed epitope within the RBS;
cross-neutralizes Ebola (EBOV), Sudan (SUDV), and,
to a lesser extent, Bundibugyo viruses; and shows
protection against EBOV and SUDV in mice and
guinea pigs. The antibody cocktail ZMappTM is
remarkably effective against EBOV (Zaire) but does
not cross-neutralize other ebolaviruses. By replacing
one of the ZMappTM components with FVM04, we
retained the anti-EBOV efficacy while extending the
breadth of protection to SUDV, thereby generating a
cross-protective antibody cocktail. In addition, we
report several mutations at the base of the ebolavirus
glycoprotein that enhance the binding of FVM04 and
other cross-reactive antibodies. These findings have
important implications for pan-ebolavirus vaccine
development and defining broadly protective anti-
body cocktails.1514 Cell Reports 15, 1514–1526, May 17, 2016 ª 2016 The Authors
This is an open access article under the CC BY-NC-ND license (http://INTRODUCTION
Filoviruses are the causative agents of severe hemorrhagic fever
in humans and nonhuman primates (NHPs) (Kuhn et al., 2014).
Members of the family Filoviridae include two marburgviruses:
Marburg virus (MARV) and Ravn virus (RAVV), and five ebolavi-
ruses: Ebola virus (EBOV), Sudan virus (SUDV), Bundibugyo vi-
rus (BDBV), Reston virus (RESTV), and Taı¨ Forest virus (TAFV)
(Kuhn et al., 2014). The EBOV (Zaire) has caused the largest
number of outbreaks, including the 2014 EBOV disease (EVD)
epidemic that led to over 28,637 cases and 11,315 deaths.
Due to the higher frequency of outbreaks caused by EBOV,
most efforts toward vaccine and therapeutic development
have focused on this agent. Several studies have shown remark-
able efficacy of antibody therapeutics against EBOV (Dye et al.,
2012; Marzi et al., 2012; Olinger et al., 2012; Pettitt et al., 2013;
Qiu et al., 2012a, 2012b, 2013a, 2014). However, until recently
(Bounds et al., 2015; Flyak et al., 2016; Frei et al., 2016; Holts-
berg et al., 2015; Keck et al., 2015), the development of
cross-protective monoclonal antibodies (mAbs) targeting multi-
ple species of ebolavirus has been lagging behind.
The filovirus surface glycoprotein, comprising disulfide-linked
subunits GP1 and GP2, is the primary target for vaccines and
immunotherapeutics (Marzi and Feldmann, 2014). The crystal
structures of the trimeric EBOV GP1,2 spike (henceforth termed
GP) in complex with KZ52 (Lee et al., 2008), a neutralizing mAbcreativecommons.org/licenses/by-nc-nd/4.0/).
derived from an EVD human survivor (Maruyama et al., 1999), as
well as SUDV GP in complex with the neutralizing mouse mAb
16F6 (Dias et al., 2011), have revealed a key mechanism of
neutralization. The three GP1 subunits form a chalice-like struc-
ture, with GP2 wrapping around GP1 and the N terminus of GP1
forming the base of the chalice (Lee et al., 2008). Both KZ52 and
16F6 contact residues within GP1 and GP2 at the base and
neutralize the virus by blocking the viral fusion with the endoso-
mal membrane (Dias et al., 2011; Lee et al., 2008). When admin-
istered prophylactically or 1 hr after infection, KZ52 protected
guinea pigs from lethal EBOV challenge (Parren et al., 2002).
However, in a single study, KZ52 did not protect against EBOV
in NHPs at the tested dosing and regimen (Oswald et al., 2007).
Several recent studies have revealed that effective post-expo-
sure protection against EBOV in primates requires a cocktail
of mAbs (Pettitt et al., 2013; Qiu et al., 2012a, 2013a) or a com-
bination of mAbs and interferon alpha (IFNa) (Qiu et al., 2013b,
2013c). Further testing of various combinations in the guinea
pig model of EBOV infection identified a highly effective cocktail
of three EBOV-specific mAbs, known as ZMappTM (Qiu et al.,
2014). ZMappTM showed 100%efficacy in NHPswhen treatment
was initiated as late as 5 days post-infection (dpi) (Qiu et al.,
2014). Single-particle electron microscopy (EM) reconstructions
of GP complexed with individual ZMappTM components (c2G4,
c4G7, and c13C6) revealed two sites of vulnerability on the
EBOVGP and elucidated the structural basis for their remarkable
efficacy (Murin et al., 2014). Of the three components of
ZMappTM, c2G4 and c4G7 target an epitope shared with KZ52
at the ‘‘base’’ of the chalice near the interface of GP1 and
GP2, whereas c13C6 binds to a highly glycosylated domain on
the top of a GP molecule known as the glycan cap (Davidson
et al., 2015; Murin et al., 2014).
While the combination of the base and glycan cap binders
thus far appeared to be most effective against EBOV, these
antibodies are virus specific, and it is not clear if the same
paradigm can be applied to broadly protective immunothera-
peutics. Although the epitopes engaged by EBOV-specific
KZ52 and SUDV-specific 16F6 overlap by ten residues (Dias
et al., 2011; Lee et al., 2008), these base binders do not cross-
react with other ebolaviruses. Neutralizing antibodies targeting
the receptor-binding site (RBS) have been described for several
viruses, including influenza (Lee and Wilson, 2015), HIV (Geor-
giev et al., 2013), SARS (severe acute respiratory syndrome) co-
ronaviruses (Coughlin and Prabhakar, 2012), and Chikungunya
virus (van Duijl-Richter et al., 2015). However, no neutralizing
antibodies have been identified that would target the RBS within
the ebolavirus glycoproteins. The filovirus RBS consists of a rela-
tively exposed hydrophilic ‘‘crest’’ and a hydrophobic ‘‘trough’’
that is exposed on marburgvirus but occluded by the glycan
cap in EBOV GP (Hashiguchi et al., 2015; Wang et al., 2016).
RBS-binding mAbs were recently identified for marburgvirus
(Flyak et al., 2015) and shown to bind to the RBS trough (Hashi-
guchi et al., 2015). Some of these antibodies also bind to EBOV
GP but only after the glycan cap is proteolytically removed by
thermolysin (Hashiguchi et al., 2015), a process that mimics
the cathepsin-mediated cleavage in endosomes (Miller and
Chandran, 2012). In contrast, no antibodies have been reported
to date that bind the prominent crest region of the RBS.Recently, we reported that pan-ebolavirus and pan-filovirus
antibodies, including two broadly neutralizing mAbs isolated
from mice and macaques that were immunized with a mixture
of engineered glycoproteins for EBOV, SUDV, and MARV and
boosted with virus-like particles (VLPs) for the three viruses
(Holtsberg et al., 2015; Keck et al., 2015). In contrast to the
base binders, these antibodies all bind, to the apex of the GP
trimer, either the inner chalice or the glycan cap. Here, we report
that one of these mAbs, FVM04, binds to the tip of the RBS
crest and blocks the interaction of EBOV GP with its endosomal
receptor Niemann-Pick C1 (NPC-1). EM reconstructions of
FVM04 complexed with EBOV GP show a unique asymmetric
mode of engagement with a single antibody per trimer. FVM04
neutralizes EBOV, SUDV, and, to a lesser extent, BDBV and pro-
tects mice and guinea pigs from lethal challenge with EBOV and
SUDV. Furthermore, replacement of one of the base binders in
ZMappTM with FVM04 retains the potency of the cocktail toward
EBOV while expanding the protective breadth of the cocktail to
include SUDV.
RESULTS
FVM04 Binds to an Exposed Region of the Filovirus RBS
We recently described several macaque-derived pan-ebolavirus
mAbs (Keck et al., 2015). One of thesemAbs (FVM04) neutralized
both EBOV and SUDV and showed significant efficacy in mice
when administered at two doses, one on the day of challenge
and one 3 dpi (Keck et al., 2015). Our studies suggested that
FVM04 targets a conformational epitope shared among all ebola-
viruses with a low level of cross-reactivity to MARV (Keck et al.,
2015). In order to define the FVM04 epitope, we used an alanine
scanning approach, where FVM04 bindingwas evaluated against
a ‘‘shotgun mutagenesis’’ mutation library of EBOV GP with 641
of 644 target residues individuallymutated.HumanHEK293Tcells
were transfected with the entire library in a 384-well array format
(one clone per well; Figure 1A) and assessed for reactivity to
FVM04 by high-throughput flow cytometry.
The epitope mapping identified EBOV GP residues K115,
D117, and G118 as critical for FVM04 binding (Figure 1). Alanine
substitutions at these residues reduced FVM04 binding to 29%,
1%, and 2% of wild-type, respectively, suggesting that these
residues constitute key contact sites for FVM04, with D117 and
G118 having the greatest energetic contribution to FVM04 bind-
ing (Figures 1B and 1C). In contrast, binding of two other pan-
ebolavirus antibodies FVM02 and FVM09 (Keck et al., 2015)
was not affected by these mutations (Figure 1C). The putative
epitope of FVM04 is positioned in a previously described region
with a crest-and-trough morphology (Bornholdt et al., 2016; Ha-
shiguchi et al., 2015) within the RBS and constitutes the tip of the
hydrophilic crest (red dotted outline in Figure 1D), which interacts
with a loop from the endosomal filovirus receptor NPC1 (Wang
et al., 2016). In contrast to this exposed tip of the crest, the trough
is lined with hydrophobic residues and occluded by the b14-b15
loopwithin the glycan cap (black dotted outline in Figure 1D). This
occlusion explains why trough-binding mAbs do not bind and
neutralize EBOV unless the glycan cap is removed by proteolysis
(Hashiguchi et al., 2015). Interestingly, while FVM04 binds well
to EBOV GP, this binding was moderately enhanced by alanineCell Reports 15, 1514–1526, May 17, 2016 1515
Figure 1. Identification of Critical Residues for FVM04 Binding
(A) A shotgun mutagenesis mutation library was constructed for EBOV GP protein, where each of the 641 amino acids were individually mutated to alanine.
Human HEK293T cells expressing themutation library were tested for reactivity tomAbs using an Intellicyt flow cytometer. A typical reactivity pattern (redwells) is
shown for a representative assay plate. Eight positive (wild-type EBOV GP) and eight negative (mock-transfected) control wells were included on each plate.
(B) The library was tested for reactivity with FVM04. Clones with <30% binding relative to that of wild-type (WT) EBOV GP yet >65% reactivity for a control mAb
were initially identified to be critical for FVM04 binding.
(C) Mutation of three individual residues reduced FVM04 binding (red bars) but had little effect on the binding of FVM02 and FVM09 (gray bars; Keck et al., 2015).
Bars represent the mean and range ([maxmin]/2) of at least two replicate data points.
(D) The FVM04 binding residues are shown in red in the crystal structure of EBOV GP. The glycan cap is shown in cyan, and the attachment points for N-linked
glycans in orange. The GP1 core is shown in purple, and parts of GP2 are seen in yellow. The RBS crest is shown in red outline and the occluded trough region is
shown in black outline.
(E) Sequence homology between filoviruses within the RBS crest region containing putative FVM04 epitope. Identical sequences among ebolavirus species and
between ebolavirus and marburgvirus are shown in red. The FVM04 binding site is boxed.
(F–H) The EBOV GP monomer is depicted as a cartoon overlay with GPCL (F), SUDV GP (G), and MARV RAVN GP (H). Putative critical EBOV contacts made by
FVM04 are shown as sticks (red) overlaid with corresponding contact residues from the overlay structure (green).substitution of N238, T240, N257, T259, N268, and T270, muta-
tions that delete three out of four glycosylation sites on the glycan
cap (Figure S1), suggesting that these glycans may modestly
interfere with FVM04 binding. Nonetheless, these data show
that FVM04 represents a prototypic pan-ebolavirus antibody
that recognizes a uniquely exposed epitope within the RBS.
The crest region is highly conserved among all ebolavirus spe-
cies, and the three residues critical for FVM04 binding are 100%
identical amongebolaviruses (Figure 1E). Anoverlay of thecrystal
structures of EBOVGP (Lee et al., 2008) with the structure of ther-
molysin-cleaved GP (GPCL) (Bornholdt et al., 2016; Wang et al.,
2016) and SUDV GP (Dias et al., 2011) showed high structural
conservation within this region and prominent exposure of these
residues on the surface of GPCL (Figure 1F) and SUDV GP (Fig-
ure 1G). While only one out of the three residues in this putative
epitope match between EBOV and MARV (Hashiguchi et al.,
2015) (Figure 1E), this region still shows a high degree of confor-
mational similarity between EBOV andMARV, with the three crit-
ical EBOV residues overlaying well with MARV D99, S101, and
G102 (Figure 1H). This may explain the low affinity of FVM04 for
MARV GP as we previously reported (Keck et al., 2015).1516 Cell Reports 15, 1514–1526, May 17, 2016EBOV-neutralizing antibodies KZ52 (Lee et al., 2008; Parren
et al., 2002), 2G4, and 4G7 (Murin et al., 2014; Qiu et al., 2012b)
bind to overlapping epitopes at the base of theGP trimer consist-
ing of residues from both GP2 and the base of GP1 (Figure 2A). In
contrast, FVM04 appears to bind the apex of the trimer, between
the glycan cap and the trimer center (Figure 2A), therefore repre-
senting a distinct class of neutralizing antibodies. In addition
to epitope-mapping information (loss-of-function analysis), the
alanine-scanning experiments revealed a striking difference
between the GP-binding patterns of these ‘‘base-binding’’ and
‘‘apex-binding’’ classes of neutralizers. While the binding of the
base binder KZ52 to all individual mutants remained consistently
below 150% of wild-type GP (Figure 2B), several single-alanine
mutations of GP had a dramatic enhancing effect (as high as
200%–300%) on FVM04 binding (Figure 2C). Out of 217 amino
acids forming thebase, alaninemutationof 23 residues increased
FVM04 binding to GP by more than 2-fold (Figure 2C; Table S1).
Most of these residues are hydrophobic, highly networked, and
not surface exposed (Figure S2; Table S1). In addition to the 23
base residues,mutation of R498 andR501, within the furin cleav-
age site separating GP1 and GP2 (Volchkov et al., 1998), also led
Figure 2. Mutations in the GP Base Affect the Exposure of the FVM04 Epitope
(A) Crystal structure of the trimeric EBOV GP complexed with KZ52 (PDB: 3CSY). The specific domains are color coded as indicated in the figure.
(B and C) Relative binding of individual point mutants of mature EBOVGP to the base binder KZ52 (B) or FVM04 (C) compared to binding to wild-type (WT) GP set
at 100%. Individualmutants are color coded in (B) and (C) based on the positioning of each residue in various structural domains according to the key shown in (B).
See also Table S1 and Figures S1 and S2.to an increase over 2-fold in FVM04 binding (Figure 2C; Table
S1). An alanine mutagenesis scan of several other cross-reac-
tive apex-binding antibodies (m8C4, 4B8, FVM09, FVM17, and
FVM20) (Holtsberg et al., 2015; Keck et al., 2015) also revealed
a similar enhancement of binding to the same alanine mutants
that enhance FVM04 binding (Table S1). These data suggest
that specific mutations in the GP base may have a global impact
on the exposure of cross-reactive epitopes in the GP1 head
domain. This finding may have major implications for the design
of pan-ebolavirus vaccines.
EM Analysis of FVM04-GP Complex
To further characterize FVM04 binding to EBOV GP, FVM04 Fab
in complex with GPDMuc was analyzed by negative-stain EM.
The binding location of FVM04 revealed an epitope consistent
with the crest residuesderivedbymutagenesis studies. Theclass
averages suggest that only one FVM04 Fab binds to each GP
trimer (Figures 3A and 3B; Figure S3). The binding of one
FVM04 Fab per trimer was also further confirmed by size exclu-
sion chromatography-multiangle light scattering (SEC-MALS)
analysis (Figure S4). It is likely that the binding orientation and
proximity to the 3-fold axis precludes additional FVM04 Fabs
from binding. In contrast, the previously characterized glycan-
cap-binding antibody c13C6, which binds in a nearby region to
FVM04, has a greater occupancy (two to three Fabs per GP
trimer) (Murin et al., 2014) (Figure 3C). Although several attempts
were made to generate a 3D reconstruction of FVM04 binding
to GP, the data failed to converge on an interpretable model,
suggesting that the crest epitope is flexible.
Cross-neutralizing Activity of FVM04
Weused several assays to evaluate the cross-neutralizing activity
of FVM04 against multiple ebolaviruses. These assays included
replication-incompetent vesicular stomatitis viruses (VSVs) pseu-
dotyped with filovirus GP and expressing Luciferase (VSV-GP-
Luc), aswell as replication-competentVSVpseudotypesexpress-
ing GFP (VSV-GP-GFP) and wild-type live virus. While the first
assay identifies only direct-entry inhibitors, antibodies inhibiting
either the entry or other stages of viral replication can be identified
by the second assay or live virus. As shown in Figure 4A, FVM04
effectively neutralized the entry of both VSV-pseudotyped EBOVandSUDV,withhalfmaximal effectiveconcentration (EC50) values
of 3.4 and 4.3 mg/ml, respectively. We also examined whether
the FVM04 neutralization is dependent on bivalent binding of full
immunoglobulin (Ig) G or whether FVM04 Fab fragment would
also mediate neutralization. EBOV entry was effectively inhibited
by FVM04 Fab with an EC50 similar to that of full IgG; however,
theneutralizingpotencyofFVM04Fab towardSUDVwasreduced
compared to that of full IgG (Figure 4B). FVM04 also effectively
neutralized replication-competent VSV pseudotyped with EBOV
or SUDV but not TAFV (Figure 4C). While FVM04 showed
low neutralizing activity toward VSV-BDBV GP-GFP, this neutral-
ization plateaued at 50%, leaving a non-neutralized subset
of infectious virions remaining (Figure 4C). We further tested
the neutralizing activity of FVM04 against authentic (wild-type)
EBOV, SUDV, and BDBV, using a plaque reduction neutralization
(PRNT) assay under BioSafety Level 4 (BSL-4) containment. The
highest neutralizing activity was observed against SUDV, while
3- to 4-fold and 20- to 30-fold higher concentrations of FVM04
were required to effectively neutralize wild-type EBOV and
BDBV, respectively (Figure 4D). As expected, FVM04 did not
neutralize MARV (Figure 4D).
Previous reports showed that mAbs targeting the trough re-
gion of the RBS do not or poorly neutralize VSV-EBOV GP but
can neutralize the pseudotyped virus after cleavagewith thermo-
lysin (VSV-EBOV GPCL), which mimics the cathepsin cleavage in
endosomes (Bornholdt et al., 2016; Flyak et al., 2015; Hashiguchi
et al., 2015). To this end, we tested whether the crest binder
FVM04 could also neutralize the endosomal form of the virus
and whether proteolytic removal of the glycan cap and mucin-
like domain (MLD) impacts its neutralizing potency. As shown
in Figure 4E, FVM04 neutralized both VSV-EBOV GPCL and
VSV-SUDV GPCL nearly 100-fold more effectively than the VSV
expressing full-length GP (compare with Figure 4C), suggesting
that cathepsin cleavage may further expose the FVM04-binding
site. Conversely, no increase in the partial neutralization of BDBV
by FVM04 was observed upon thermolysin cleavage (Figure 4E).
Inhibition of NPC1 Binding
Given the location of the FVM04 epitope and the antibody’s
dramatically increased neutralizing efficacy upon thermolysin
cleavage,wehypothesized that FVM04blocksbindingof cleavedCell Reports 15, 1514–1526, May 17, 2016 1517
Figure 3. Single-Particle Negative-Stain EM
Analysis of FVM04 Fab Bound to EBOV
GPDMuc
(A) Reference-free 2D class averages of the com-
plex illustrate that only a single FVM04 Fab binds
to the GP trimer near the glycan cap at the trimer
apex. Scale bar represents 100 A˚.
(B)Twoexemplar classaverageshavebeencolored
to highlight FVM04 (blue) and the GP trimer (green).
(C) Example class average of the glycan-cap-bind-
ing antibody c13C6 (orange) (Murin et al., 2014) that
also binds at the GP trimer (green) apex. Relative to
c13C6, FVM04 binds closer to the trimer 3-fold axis
and is bent inward.
See also Figures S3 and S4.EBOV GP (GPCL) to its endosomal receptor NPC1. Binding of
FLAG-tagged soluble NPC1 domain C to biotinylated VSV-
EBOV GPCL immobilized on streptavidin-coated plates was
tested in the presence and absence of FVM04. As shown in Fig-
ure 4F, FVM04 exhibited concentration-dependent inhibition of
NPC-1 binding toGPCL, suggesting that the inhibition ofGPbind-
ing to its endosomal receptor is one likelymechanismof action for
FVM04.
Affinity Measurements
We used biolayer interferometry (BLI) to measure the affinity
of FVM04 binding to EBOV, SUDV, or BDBV GP ectodomains
(GPDTM). FVM04 was bound to protein G sensors and exposed
to a range of GPDTM concentrations (Figure 5). The association
and dissociation of FVM04 to EBOV and SUDV GPDTM fit a
1:1 binding model (Figures 5A and 5B). The KD for EBOVGPDTM
was calculated to be 2.2 ± 0.1 nM, with a ka (association rate) of
(2.5 ± 0.1)3 104/M sec and a kd (dissociation rate) of (5.4 ± 0.1)3
105/s. The affinity of FVM04 for SUDV GPDTM was slightly
higher, with a KD of 9.1 ± 0.2 nM, a ka of (6.0 ± 0.1) 3
104/M sec, and a kd of (5.4 ± 0.1) 3 10
4/s. The affinity of
FVM04 toEBOVandSUDVGPDTMwasalso analyzed in anaddi-
tional experiment using anti-human Fc-coated sensors, and the
KD values were found to be similar. Interestingly, the binding of
FVM04 to BDBV GPDTM was best described with a 2:1 binding
model, with two dissociation constants of KD
1 = 570 ± 50 nM
and KD
2 = 31 ± 1 nM (Figure 5C). The initial association with
FVM04 is within the same range of EBOV GPDTM and SUDV
GPDTM, with a ka
1 of (3.8 ± 0.1) 3 104/M sec, but the second
association step is 4-fold slower, with a ka
2 of (1.1 ± 0.1) 3
104/M sec. The dissociation rate of BDBV GPDTM from
FVM04 is the fastest among all three proteins, with a kd
1 of (2.2
± 0.1) 3 102/s, and a kd
2 of (3.3 ± 0.1) 3 104/s. Collectively,
this kinetics analysis offers a biophysical explanation for the
differential neutralization profiles between the three viruses.1518 Cell Reports 15, 1514–1526, May 17, 2016FVM04 exhibits potent neutralization of
both EBOV and SUDV, consistent with
a high affinity for both glycoproteins
in vitro (nanomolar range, KD), but only
a modest neutralization activity against
BDBV consistent with poorer binding
profiles toward this GP. The difference inbinding between EBOV/SUDV and BDBV GP is most evident in
the biphasic dissociation phase for BDBV, which is dominated
by a dissociation rate (kd) that is two orders of magnitude faster
than for EBOV or SUDV GP.
Efficacy in Mice
Wepreviously reported the efficacyof FVM04 in amousemodel of
EBOVwhen administered at two doses starting immediately after
infection (Keck et al., 2015). Here, we expanded these studies to
post-exposure treatment in both the EBOV model and a recently
developed mouse model for SUDV (Brannan et al., 2015). First,
we evaluated the delayed administration of a single dose of
FVM04. Groups of ten mice were infected with 100 plaque-form-
ing units (PFU) of mouse-adapted EBOV (MA-EBOV) (Bray et al.,
1999) and treated with a single intraperitoneal (i.p.) injection of
10mg/kg (200 mg permouse) of FVM04 either 1, 2, or 3 dpi. A sin-
gle injection of FVM04 at 1 dpi led to full protection from lethal
challenge (p < 0.0001; determined by Manel-Cox method), while
delayed treatment on day 2 or day 3 (peak of viremia) resulted in
80% (p = 0.0012) and 30% (p = 0.108) protection, respectively
(Figure 6A). Consistent with survival data, mice treated at 1 dpi
showednoweight loss or sign of disease (Figure 6A).Mice treated
on2or 3dpi lost amaximumof 8%and10%bodyweight, respec-
tively, compared to 18% weight loss in the control group, and
milder clinical signs of disease were observed (Figure 6A). Then,
we evaluated the dose response by treating the mice 2 dpi
with 10, 5, or 2.5 mg/kg (200, 100, or 50 mg per mouse) of
FVM04 or PBS as control. In this study, both 10 and 5 mg/kg
FVM04 provided full protection (p < 0.0001), while 70% of the
mice receiving 2.5mg/kg survived the challenge (p = 0.0004) (Fig-
ure 6B). PBS-treated mice lost about 13% of their body weight
before succumbing to infection, while mice treated with FVM04
showed less weight loss and less severe disease, as determined
by health scores (Figure 6B). These data clearly indicate the
post-exposure efficacy of FVM04 at relatively low doses.
Figure 4. Neutralization of Filoviruses and Inhibition of EBOV GP/NPC-1 Interaction by FVM04
(A) FVM04 was preincubated at different concentrations with VSV-EBOV GP-Luc or VSV-SUDV GP-Luc and added to Vero cells in 96-well plates. Luciferase
activity was measured after 48 hr and percent neutralization was calculated in comparison with untreated virus.
(B) Neutralization assay was performed as in (A) using purified FVM04 Fab fragment.
(C) Neutralization of rVSV-GFP expressing full-length GP of EBOV, SUDV, or TAFV, or GPDMuc of BDBV.
(D) Plaque reduction neutralization of wild-type EBOV, SUDV, BDBV, or MARV by FVM04.
(E) Neutralization of VSV-EBOVGPCL and VSV-SUDVGPCL by FVM04.
(F) VSV-EBOVGPCL was immobilized on streptavidin-coated plates and incubated with Flag-NPC1 in the presence or absence of various concentrations of
FVM04. BoundNPC1was detected using anti-Flag antibody-HRP conjugate. The relative binding of NPC1was calculated in the presence of inhibiting antibody in
comparison to the no-antibody control and plotted as percent binding.
Error bars represent SEM.Efficacy of FVM04 was further tested in mice in which the
genes for IFNa/IFNb (interferon beta) receptor are knocked out
(IFNabR/) (Brannan et al., 2015). Groups of seven 4-week-
old IFNabR/ mice were infected with 1,000 PFU of SUDV fol-
lowed by i.p. injection of 10 mg/kg of anti-SUDV GP mAb 16F6
at 1 and 3 dpi, or FVM04 at 1 dpi. A control group of six mice
received no treatment after the infection. The SUDV-specific
16F6 fully protected mice with minimal weight loss or signs of
disease (Figure 6C). Five out of seven mice treated with FVM04
were protected from lethal challenge, while the effect on average
weight loss and health scores was not apparent (Figure 6C).
Efficacy in Guinea Pigs
EfficacyofFVM04wasalsoexamined inguineapigsusingguinea-
pig-adapted EBOV and SUDV (GPA-EBOV and GPA-SUDV,
respectively) (Volchkov et al., 2000; Wong et al., 2015). Four
groups of six guinea pigs were challenged with either 1,000 3
LD50 (the median lethal dose) of GPA-SUDV or GPA-EBOV
followed by a single i.p. injection of 5 mg FVM04 (15 mg/kg) or
vehicle control at 1 dpi. Animals were monitored for 16 days for
weight change and 28 days for survival. A single injection of
FVM04 protected all guinea pigs from GPA-SUDV challenge,
while the controls succumbed to infection within 10–13 days
(p = 0.0004) (Figure 7A). While the controls lost up to 40% body
weight after the GPA-SUDV challenge, no weight loss or sign ofdisease was observed among FVM04-treated animals (Fig-
ure 7A). All DPBS-treated guinea pigs infected with GPA-EBOV
succumbed to infection within 6–7 days, while two out of six
FVM04-treated animals survived the challenge, and the remaining
died between 9 and 11 dpi (p = 0.0012) (Figure 7B). The median
survival was 7 days for the control group and 11 days for the
FVM04-treated group. Control animals lost over 25% of their
weight before dying, while the FVM04-treated animals initially
gained weight followed by a moderate weight loss (5%) 10–
15 days post-challenge (Figure 7B).
The partial protection against EBOV is consistent with previ-
ous reports indicating that an antibody cocktail is required
for effective post-exposure protection against EBOV in guinea
pigs and NHPs (Qiu et al., 2014). ZMappTM, consisting of the
two base binders c2G4 and c4G7 and the glycan cap binder
c13C6, was selected for testing in NHPs based on significant,
but partial, protection in guinea pigs (four out of six) when admin-
istered once at 3 dpi (Qiu et al., 2014). Based on the afore-
mentioned study, we hypothesized that replacing one of the
ZMappTM components with FVM04 would lead to an effective
EBOV cocktail that is also protective against SUDV. We selected
themAb c4G7 to be replaced, since it binds to an epitope closely
overlapping the c2G4 epitope (Audet et al., 2014; Davidson et al.,
2015; Murin et al., 2014). First, we tested whether FVM04 alone
(5 mg) or a cocktail of c2G4/c13C6/cFVM04 (1.6 mg each) wouldCell Reports 15, 1514–1526, May 17, 2016 1519
Figure 5. Kinetic Analysis of FVM04 Binding to GP
(A–C) The sensograms show the association and dissociation of EBOV (A), SUDV (B), or BDBV (C) GPDTM binding to FVM04 immobilized on protein G sensors.
Binding to EBOV GPDTM and SUDV GPDTM fit to a 1:1 binding model, whereas BDBV GPDTM fit to a 2:1 binding model. Analyzed concentration ranges are
indicated (colored), and the fits are shown as red dashes. On-rate, off-rate, and KD values for each of the three proteins are shown below the sensograms.protect against GPA-SUDV when administered at 3 dpi. While all
GPA-SUDV-infected control animals died within 10–14 days, all
FVM04-treated animals and five out of six animals treated with
the cocktail survived the challenge (Figure 7C). The protection
was highly significant, with p = 0.0008 for both treatment groups
compared with the controls. Animals treated with FVM04 ex-
hibited no weight loss, while control animals lost an average of
25% body weight (Figure 7C). While the animals treated with
the cocktail also showed no weight loss on average (Figure 7C),
the only fatal case in this group lost 17% of its body weight
before dying on day 14 post-infection.
The cocktail consisting of FVM04, c13C6, and c2G4 was also
tested in the GPA-EBOV model. Four out of six animals treated
with a single dose of 5 mg cocktail (1.6 mg of each component)
at 3 dpi survived the challenge, while all control animals suc-
cumbed to infection within 7–9 days (p = 0.0061) (Figure 7D).
The control animals lost an average of 20% of their weight, while
the average weight within the cocktail-treated group showed a
steady increase over 16 dpi (Figure 7D). Of the two cocktail-
treated animals that died, one lost about 9% body weight by
the day of death (7 dpi), and the second animal actually gained
12% body weight before dying on day 8. As a comparison, Fig-
ure 7E shows compiled survival and weight loss data from three
studies that we have performed with ZMappTM (5 mg per animal;
n = 20). A survival rate of 67% in guinea pigs for the cocktail of
FVM04/c13C6/c2G4 is well within the range of protection af-
forded by ZMappTM, as shown here and reported previously
(Qiu et al., 2014).
DISCUSSION
The devastating 2014 EVD epidemic in West Africa is a sobering
reminder of the global threat of filovirus infections. This outbreak
reached unprecedented dimensions, despite the fact that the
majority of efforts to develop vaccines and therapeutics over
the past decade was focused on the same ebolavirus that1520 Cell Reports 15, 1514–1526, May 17, 2016caused this epidemic. Given the uncertainties about the natural
reservoir and the zoonotic dynamics of filoviruses, it is impos-
sible to predict the species or location of future outbreaks.
Thus, broadly protective vaccines and therapeutics are urgently
needed to cope with this emerging threat. Recent reports indi-
cate that mAbs against GP are effective as post-exposure treat-
ments for ebolavirus hemorrhagic fever (Pettitt et al., 2013; Qiu
et al., 2014). ZMappTM, a cocktail of three mAbs against EBOV
GP, is among the most advanced therapeutic candidates and
has exhibited remarkable efficacy in symptomatic EBOV-in-
fected NHPs (Qiu et al., 2014). However, these immunothera-
peutic candidates are species specific and mostly target EBOV
(Zaire) only.
According to the current dogma in the field, a combination of
antibodies is required for effective control of EBOV infection,
and antibodies in current cocktails include those that target the
base of the trimeric GP, as well as those that bind the apex of
the trimer in the glycan cap (Murin et al., 2014). Recently, engi-
neered bispecific antibodies targeting the GP base of both
EBOV and SUDV were shown to provide post-exposure protec-
tion in mice (Frei et al., 2016). Despite the structural overlap of
16F6 (SUDV-specific) and KZ52 (EBOV-specific) to date, no
cross-binding antibody that targets the GP base epitope on a
canonical IgG framework has been described. Thus, antibody
cocktails with expanded neutralizing and protective breadth are
likely to engage novel epitopes. We have recently identified a
set of pan-ebolavirus and pan-filovirusmAbs that target phyloge-
netically conserved sites within the glycan cap and core GP1,
including two mAbs (m8C4 and FVM04) that effectively cross-
neutralize EBOV and SUDV, the two most divergent filoviruses
(Holtsberg et al., 2015;Keck et al., 2015). Here,we report full char-
acterization of the pan-ebolavirus mAb FVM04 and demonstrate
that it targets a uniquely exposedepitopewithin theRBSandcon-
veys post-exposure protection against both EBOV and SUDV.
The receptor-binding unit of filovirus GP has an ocean-wave
morphology with a recessed trough and a rising crest (Bornholdt
Figure 6. Post-exposure Efficacy of FVM04 in a Mouse Model of EBOV and SUDV Infection
(A and B) Groups of ten BALB/c mice were infected intraperitoneally with 100 PFU of MA-EBOV and treated intraperitoneally with the doses and at time points
indicated in the figure or left untreated.
(C) Three groups of IFNabR/mice were infected with 1,000 PFU of SUDV; one group (n = 7) received two i.p. injections of 16F6 at 1 and 3 dpi, a second group
received FVM04 once at 1 dpi, and a third group was left untreated. Mice were monitored for 21 days for survival, weight change, and signs of disease.et al., 2016; Hashiguchi et al., 2015; Wang et al., 2016). The sur-
face of the trough is lined with hydrophobic residues from a1 and
b4 strands and their connecting loop in ebolavirus GP and resi-
dues 63–74 of MARV GP (Bornholdt et al., 2016; Hashiguchi
et al., 2015). In contrast, the wave crest (strands b7 and b9 and
their connecting loops in ebolavirus GP) is hydrophilic and con-
tains basic residues that undergo electrostatic interactions with
the filovirus host receptor NPC-1 (Bornholdt et al., 2016; Wang
et al., 2016). The recessed trough is occluded by specific inter-
action of residues from the glycan cap, with the hydrophobic
lining of the trough blocking its accessibility on the surface of
EBOV GP (Hashiguchi et al., 2015). Only after cathepsin-medi-
ated cleavage within endosomes removes the glycan cap are
the residues within the ebolavirus GP trough unmasked for spe-
cific interactionwith NPC1 (Bornholdt et al., 2016; Krishnan et al.,
2012; Miller et al., 2012). These findings provide a structural
explanation for the observation that MARV-neutralizing anti-
bodies such as MR78 and MR72 (Flyak et al., 2015) bind full-
length MARV GP, in which the trough is apparently exposed,
but bind and neutralize EBOV only after thermolysin cleav-
age and removal of the glycan cap (Hashiguchi et al., 2015).
In contrast, the tip of the crest is accessible on the surface
of GP trimer (Bornholdt et al., 2016; Hashiguchi et al., 2015).Our alanine-scanning mutagenesis analysis reveals K115,
D117, and G118 (positioned at the tip of the crest) as critical res-
idues for FVM04 binding. Bornholdt et al. recently demonstrated
that mutations of K114 and K115 to alanine significantly reduce
NPC-1 binding by GPCL, while mutating these residues to gluta-
mic acid completely abrogates GP interactions with NPC-1, sug-
gesting that these basic residues are involved in receptor binding
(Bornholdt et al., 2016). Moreover, the recently solved X-ray
crystal structure of a GPCL-NPC-1 domain C protein complex re-
veals that a loop in NPC1 domain C directly contacts the basic
crest (Wang et al., 2016). Here, we show that FVM04 binding
specifically blocks the interaction of GPCL with NPC-1. Lately,
Corti et al. (2016) also reported an EBOV-specific antibody that
binds to the EBOVGP glycan cap and the RBS region and blocks
GP interaction with NPC-1 (Misasi et al., 2016). Thus, FVM04
represents a distinct cross-neutralizing antibody that binds an
exposed epitope within the ebolavirus RBS and neutralizes the
virus, at least in part, through blockade of receptor interaction.
The primary amino acid sequence of the crest region is highly
conserved among all ebolaviruses and modestly homologous
between ebolaviruses and marburgviruses. The tip of the crest,
which includes FVM04 binding sites, also shows high structural
homology between EBOV and SUDV and, to a lesser extent,Cell Reports 15, 1514–1526, May 17, 2016 1521
Figure 7. Efficacy of FVM04 Treatment and an FVM04-Containing
Cocktail in Guinea Pig Models of SUDV and EBOV Infection
(A and B) Efficacy of a single i.p. dose of 5 mg per animal FVM04 (15 mg/kg)
injected at 1 dpi compared to control group receiving DPBS in animals chal-
lenged with GPA-SUDV (A) or GPA-EBOV (B), with six animals per group.
(C) Groups of six guinea pigs were challenged with GPA-SUDV and treated
with either DPBS; 5 mg per animal of FVM04; or 1.6 mg per animal each of
FVM04, c2G4, and c13C6 at 3 dpi.
(D) Guinea pigs (six animals per group) were infected with GPA-EBOV and
treated with 1.6 mg per animal each of FVM04, c2G4, and c13C6 at 3 dpi.
(E) Compiled data of three experiments with ZMappTM. Guinea pigs were in-
fected with GPA-EBOV and treated with DPBS (n = 19) or 5 mg per animal of
1522 Cell Reports 15, 1514–1526, May 17, 2016between EBOV and MARV GP. While FVM04 effectively neutral-
ized both EBOV and SUDV, it only exhibited partial neutralization
of BDBV. Our previous results indicated that FVM04 binds to
BDBV GP with an ELISA EC50 comparable to those of EBOV
and SUDV (Keck et al., 2015). However, our kinetic analysis in
this report showed that FVM04 has a very rapid off rate for
BDBV GP, providing a possible explanation for low neutralizing
activity toward BDBV. The amino acid sequence of the EBOV
and BDBV GP crest regions only differ in positions 112 (glutamic
acid in EBOV versus aspartic acid in BDBV) and 116 (proline in
EBOV versus alanine in BDBV). In our alanine-scanning analysis,
the E112A and P116A mutations in EBOV GP did not alter the
binding to FVM04 (106% and 115% of wild-type respectively).
However, it is possible that the residues 112 and 116 influence
the positioning of the key residues 115, 117, and 118 or are
part of the epitope directly but at a lower energetic level that
cannot be captured by the cell-surface staining assay. FVM04
did not neutralize VSV pseudotyped with TAFV GP, which also
differs from EBOV GP in the same crest residues as BDBV with
alanine and valine in positions 112 and 116, respectively. None-
theless, FVM04 is an effective neutralizer of the most virulent
ebolaviruses EBOV and SUDV.
An interesting feature of FVM04 is its asymmetric binding toGP
in contrast to antibodies such as ZMappTM components (Murin
et al., 2014) and KZ52 (Lee et al., 2008). Class averages from
the analysis of negative-stain EM of FVM04 Fab bound to
GPDMuc revealed that it binds with a stoichiometry of one Fab
per trimer. The position of FVM04 in EM studies is consistent
with the mutational analysis. Together, these results suggest
that this mAb binds with a more angled pose than c13C6, which
binds at the top of GP as well but perpendicular to the plane of
the viral membrane (Murin et al., 2014). Although we have not
quantitatively established with solution studies that only a single
FVM04 Fab is capable of binding, even at saturating concentra-
tions, it seems reasonable from the EM-derived images that the
angle of approach for a single FVM04 Fab occludes the other po-
tential binding sites on the other two subunits. Further studies are
required to elucidate the implications of this binding morphology
on neutralization and in vivo efficacy, but a tantalizing possibility
is that fewer FVM04 IgGmolecules bind the GP trimer than other
IgGs on average. Lower requirement for occupancy could, in
theory, provide a therapeutic advantage because less antibody
would be required for neutralization and render the IgG less sus-
ceptible to decoy antigens such as sGP or GP spike on defective
particles. For example, studies performedwith anti-EBOVequine
Ig clearly showed rapid reduction in EBOV-specific equine IgG
titer during thepeakof viremia inNHPs,while total equine IgG titer
remained constant (Jahrling et al., 1996), suggesting high anti-
body consumption during infection. Single-site occupancy could
alsopotentially leavemoreof theGPsurfaceexposed in themAb-
GP complex, providing additional opportunities for engagement
of other epitopes by other antibodies in a cocktail.
While the FVM04 epitope is accessible, the binding is probably
not entirely free of steric hindrance. Our previous report indicatedZMappTM (n = 20) at 3 dpi. Challenge was performed with 1,000 3 LD50 of
GPA-SUDV or GPA-EBOV as indicated. Survival wasmonitored for 21 dpi, and
weights were monitored for 16 days dpi.
that FVM04 binding to GPwas slightly increased after removal of
MLD and the glycan cap (Keck et al., 2015), and data in Figure 4E
show that FVM04 neutralizes the virus carrying GPCL more effec-
tively than full-length GP. Interestingly, our mutagenesis studies
revealed that, in contrast to KZ52, binding of FVM04 was sub-
stantially enhanced when certain residues within the base of
the GP (GP2 and N terminus of GP1) were mutated to alanine.
Most of these mutations also increased binding of other cross-
reactive antibodies that we had previously reported (Holtsberg
et al., 2015; Keck et al., 2015), such as 4B8, m8C4, FVM09, and
FVM20. These residues are mostly hydrophobic and buried in
the structure, suggesting that single-point mutations within the
basemay loosen up the apex, exposing cross-reactive epitopes.
This findingmayhave important implications for thedevelopment
of pan-ebolavirus vaccines if suchmutationscanbe incorporated
into vaccines to improve their potency or breadth of protection.
Efficacy studies in mice and guinea pigs showed the high ther-
apeutic value of FVM04. Full protection from EBOV infection was
observed 2 dpi with as little as 100 mg per mouse, and a lower
dose of 50 mg per mouse showed partial but significant protec-
tion. A small-scale study in IFNabR/ mice showed 71%
protection from lethal SUDV challenge when FVM04 was admin-
istered 1 dpi. These data show that FVM04 compares well with
the post-exposure efficacy (2 dpi) of EBOV-specific mAbs 1H3,
2G4, and 4G7 as reported (Qiu et al., 2012b), while expanding
the breadth of protection to include SUDV.
The guinea pig model of EBOV infection is considered a
substantially more stringent model for screening of therapeutics
(Cross et al., 2015; Parren et al., 2002; Qiu et al., 2012b), Partic-
ularly, the testing of therapeutics at 3 dpi in this model is partic-
ularly stringent, with good predictive value for efficacy in NHPs
(Qiu et al., 2014). Recently, Wong et al. also reported the devel-
opment of a guinea pig model of SUDV infection (Wong et al.,
2015). The GPA-SUDV causes a uniformly lethal infection, with
the major hallmarks of SUDV infection, including lymphadenop-
athy, increased liver enzyme activities, and coagulation abnor-
malities (Wong et al., 2015). We used both of these models in
the present study to evaluate the efficacy of FVM04.
A single injection of FVM04 (5 mg) at 1 or 3 dpi fully protected
guinea pigs against GPA-SUDV infection with no signs of dis-
ease. This suggests that FVM04 alone may be sufficient to con-
trol SUDV infection. To date, no SUDV antibodies have been
tested in NHP studies; thus, it is not known how protection in
rodent models relates to efficacy against SUDV in NHPs. In
contrast, in the EBOV guinea pig model, a protection level of
more than60%, 3 dpi, at a total dose of 5mg is a good indicator
of efficacy in NHPs. In fact, the ZMappTM cocktail that fully pro-
tected NHPs at 5 dpi was selected based on partial efficacy at 3
dpi in guinea pigs (Qiu et al., 2014). In the GPA-EBOV-infected
guinea pigs, FVM04 protected two out of six animals when
administered at 1 dpi. While the protection level of 33%was sta-
tistically significant, it was lower than the reported protection
level of 60% at 1 dpi afforded by c2G4 or c4G7 (Qiu et al.,
2012b). These data suggested that, while FVM04 alone may be
sufficient for SUDV, more efficient protection against EBOV
would require a cocktail. Given that c2G4 and c4G7 target over-
lapping epitopes (Murin et al., 2014), we reasoned that 4G7 may
be a good candidate for replacement by FVM04. This led to acocktail of FVM04/c2G4/c13C6 that protected five out of six
guinea pigs against SUDV and four out of six animals against
EBOV. This level of protection against EBOV is comparable
with historical efficacy data of ZMappTM (Figure 7E) (Qiu et al.,
2014). These data demonstrate that a cocktail of FVM04,
c13C6, and c2G4, is as effective as ZMappTM against EBOV
while expanding the breadth of protection to include SUDV.
The efficacy of these cocktails must be further tested in future
NHP studies; however, these data position FVM04 as a strong
candidate to be a component of a pan-ebolavirus therapeutic
cocktail.
EXPERIMENTAL PROCEDURES
Antibody Production
FVM04 was produced in HEK293 cells transfected with the plasmid encoding
IgH and IgL using polyethylenimine (Polysciences) and purified by protein A
chromatography, as described previously (Keck et al., 2015). For ZMappTM
production, N. benthamiana plants genetically modified to produce homoge-
nous mammalian N-glycans of the GnGn glycoform were grown for 4 weeks
in an enclosed growth room (20–23C) and used for vacuum infiltration as
described previously (Hiatt et al., 2014). Seven days later, the mAb was ex-
tracted from the leaf tissue and purified via protein A chromatography, and
endotoxin was removed using an Acrodisc Unit with Mustang Q Membrane
(Pall Life Sciences). For Fab production, FVM04 IgG was incubated in 2%
papain for 2 hr at 37C, and the reaction was quenched with 50 mM iodoace-
tamide. The Fc portion was removed via protein A affinity, and the Fab was
further purified via S75 SEC.
Shotgun Mutagenesis Epitope Mapping
Alanine-scanningmutagenesis of an expression construct for full-length EBOV
GP (strain Mayinga-76) (Davidson et al., 2015) changed residues 33–676 to
alanine (and alanine residues to serine) to create a library of clones, each rep-
resenting an individual point mutant, covering 641 of 644 residues. Clones
were individually arrayed into 384-well plates, transfected into HEK293T cells,
and allowed to express for 22 hr. Cells were incubated with primary antibody
and then with an Alexa-Fluor-488-conjugated secondary antibody (Jackson
ImmunoResearch Laboratories). After washing, cellular fluorescence was
detected using the Intellicyt high-throughput flow cytometer (Intellicyt). Back-
ground fluorescence was determined in vector-transfected control cells. mAb
reactivity against each mutant GP clone was calculated relative to wild-type
GP reactivity by subtracting the signal from mock-transfected controls and
normalizing to the signal fromwild-type GP-transfected controls. Mutated res-
idues within clones were identified as critical to a test mAb epitope if they did
not support reactivity of the mAb but did support the reactivity of other control
EBOV mAbs. This counter-screen facilitates the exclusion of GP mutants that
are locally misfolded or have an expression defect. The detailed algorithms
used to interpret shotgun mutagenesis data are described elsewhere (patent
application 61/938,894; Davidson and Doranz, 2014).
Cell Lines
All cell lines were obtained from ATCC. Vero and HEK293T cells were main-
tained in DMEM (Life Technologies) and supplemented with 10% fetal bovine
serum (FBS) (AtlantaBiologicals) and 1%penicillin-streptomycin (Life Technol-
ogies). BHK-21 andVero cells were grown in Eagle’sminimal essential medium
(EMEM) (Corning) supplemented with 10% FBS and 1% penicillin-strepto-
mycin. All cell lines were maintained in a humidified 37C, 5% CO2 incubator.
Negative-Stain EM Studies
EBOV GPDMuc and FVM04 were each individually purified. EBOV GPDMuc
was combined with a 10-fold molar excess of FVM04 Fab and incubated over-
night at 4C.The complexwas further purifiedbySECwith anS200i column (GE
Healthcare) equilibrated in Tris-buffered saline (TBS). The complexwas depos-
ited onto a carbon-coated 400 copper mesh grid and subsequently stained
with 1% uranyl formate. Grids were loaded into a Tecnai T12 Spirit at 120keVCell Reports 15, 1514–1526, May 17, 2016 1523
and imaged using this Tietz TemCam-F416 CMOS camera at 52,0003magni-
fication at a nominal defocus of1.5mM.Micrographswere collected automat-
ically using Leginon (Suloway et al., 2005) andprocessedwithin Appion (Lander
et al., 2009). DogPicker (Voss et al., 2009) was used to automatically pick par-
ticles in the raw micrographs and placed into a 2D stack. Initial reference-free
2D classification was undertaken in XMIPP (Sorzano et al., 2004), and particles
that did not correspond to EBOV GPDMuc bound to FVM04 (e.g., noise or
amorphous particles) were removed at this point, resulting in a final stack of
13,139 particles. The remaining 13,139 particles were then processed in two
subsequent rounds of reference-free 2D classification in Relion 1.4 (Scheres,
2012), resulting in a final particle count of 8,208. Approximately half of the final
2D class averages had identifiable complexes of EBOV GPDMuc bound to
FVM04. Images were created in UCSF Chimera and Adobe Photoshop.
SEC-MALS
To determine the absolute molecular weight of EBOV GPDmuc, we first per-
formed SEC-MALS using conjugate analysis to account for glycan content.
To determine the number of FVM04 Fab molecules bound to EBOV GPDmuc
trimer, SEC-MALS was repeated with EBOV GPDmuc that had been com-
plexed with excess FVM04 Fab for 6 hr at room temperature. A Superdex
200 SEC column was coupled in line with the following calibrated detectors:
(1) a MiniDawn Treos MALS detector (Wyatt Corporation) and (2) an Optilab
T-reX refractive index (RI) detector (Wyatt Corporation). The Astra VI software
(Wyatt Corporation) was used to combine these measurements to determine
the absolute molar mass of the eluted proteins.
Neutralization Assays
Two different neutralization assays based on pseudotyped recombinant
VSV-expressing filovirus GP were used: a replication-defective recombinant
Indiana VSV (rVSV)-GP-Luc expressing firefly luciferase and a replication-
competent rVSV expressing GFP (rVSV-GFP).
rVSV-GP Luciferase Pseudotype Assay
Pseudotyped viruses were generated based on a modification of a previously
published method (Whitt, 2010). HEK293T cells (80% confluency) were trans-
fected with plasmids encoding EBOV GP, MARV GP, or SUDV GP using
Fugene HD (Promega) according to the manufacturer’s protocol. The next
day, these cells were infected with rVSV-DGP pseudotype (Kerafast) at an
MOI of 3, and the virus was washed off after 1 hr with DPBS. The next day,
the supernatant was collected and clarified by centrifugation. To titer the pseu-
dotyped virus, BHK-21 cells were transfected in six-well plates with pCAGGS
VSV-G (Kerafast), and after 48 hr, serial dilution of VSV-EBOV-GP-Luc or VSV-
SUDV-GP-Luc pseudotype was added to each well for 1 hr before the addition
of 0.9% agar in DMEM. The next day, wells were fixed with 5% glutaraldehyde
for 30min before removing the agar and staining with crystal violet to count the
plaques. The details of the luciferase assay for the determination of VSV-GP-
Luc infectivity were previously described (Keck et al., 2015). Data were fit to a
4PL curve using GraphPad Prism 6. Percent neutralization was calculated
based on wells containing virus only.
rVSV GP-GFP Assay
rVSVs expressing EGFP, aswell as EBOVorMARVGP in place of VSV-G, were
described previously (Miller et al., 2012; Ng et al., 2014; Wong et al., 2010).
rVSVs bearing TAFV, SUDV GP, or BDBV GPDMuc were generated by the
same method. VSV particles containing cleaved GP (GPCL) were generated
by incubating rVSV-GPs with thermolysin (200 mg/ml) for 1 hr at 37C, followed
by treatment with phosphoramidon (1 mM), and reaction mixtures were used
immediately. Infectivity of rVSVs was measured by counting EGFP-positive
cells at 12–14 hr post-infection using a CellInsight CX5 automated microscope
and onboard software (Thermo Scientific). For neutralization experiments,
serial dilutions of mAbs were incubated with the rVSV-GP for 1 hr at room tem-
perature. Monolayers of Vero cells seeded in 96-well plates were inoculated
with the mAb-virus mixture in triplicate and then incubated at 37C overnight.
Infection was scored 12 hr to 16 hr post-infection by the enumeration of eGFP+
cells and normalized to no-antibody control taken to represent 100%.
PRNT Assay
Antibody at indicated concentrations was incubated with 100 PFU of EBOV
(Kikwit-95) or SUDV (Boniface) at 37C, 5% CO2, and 80% humidity for 1 hr.1524 Cell Reports 15, 1514–1526, May 17, 2016The mixture was then added to Vero cells in six-well plates and incubated
for 1 hr. Cells were then overlaid with a mixture of one part 1% agarose (Sea-
kem) and one part 2X Eagle’s basal medium (EBME), 30 mM HEPES buffer,
and 5% DFBS and incubated at 37C, 5% CO2, and 80% humidity. A second
overlay containing 5% neutral red was added 6–7 days later, and plates were
incubated overnight. Plaques were counted the following day, and percent
neutralization was determined by comparing to control wells.
Antibody-Mediated Inhibition of EBOV GP-NPC1 Binding
Thermolysin-cleaved VSV-GP (rVSV-GPCL) was incubated with a functional-
spacer-lipid reagent conjugated to biotin (FSL-biotin; Sigma) to allow incorpo-
ration into viral membrane, and the resulting biotinylated viral particles were
then captured onto streptavidin-coated plates, as described previously (Ng
et al., 2014). Plates were then washed and blocked with 3% BSA-PBS buffer.
Serial dilutions of antibodies were added to virus-coated plates, and after
washing, soluble FLAG-tagged NPC1 domain C protein (2 nM) was added
to each well. Plates were washed, and the extent of NPC1 binding to rVSV-
GPCL was detected using an anti-FLAG-HRP (horseradish peroxidase) anti-
body conjugate. All incubations were performed for 1 hr at 37C. Binding
was expressed as percentage of the maximal binding signal obtained with
no-antibody control.
Affinity Measurements Using Octet
Kinetics experiments were performed on the ForteBio Octet Red96 platform.
Data were collected at 25Cwith orbital shaking at 1,000 rpm in 200 ml. Protein
G or Anti-human Fc sensors (ForteBio) were equilibrated in kinetics buffer (13
PBS, 0.1% BSA, and 0.02% Tween-20) for 10 min prior to loading with
10 mg/ml FVM04 antibody for 2 min. A stable baseline was established in
kinetics buffer for 1 min before the FVM04-coated sensors were added to a
range of EBOV, SUDV, or BDBV GPDTM concentrations. The association
step of GPDTM with FVM04 proceeded for 2 min before allowing the GPDTM
to dissociate into kinetics buffer for 10 min. A reference sensor without FVM04
was used to account for nonspecific binding of GP to the sensor. The data
were fit globally to a 1:1 or 2:1 Langmuir binding model using ForteBio data
analysis software 9.0.
Animal Challenge Studies
Mouse Challenge Studies with EBOV
Female BALB/c mice (6–8 weeks old) were purchased from Charles River Lab-
oratories. Mice were exposed to an i.p. dose of 100 PFU of (Mayinga strain)
MA-EBOV suspended in PBS. Antibodies were delivered at the indicated i.p.
doses and time points after exposure. Control mice were treated with PBS
or left untreated. Mice were observed daily for clinical signs of disease,
including but not limited to, reduced grooming and hypoactivity, and group
weights were recorded through day 14. Observations were increased to amin-
imumof twice daily whenmice exhibited signs of disease. Moribundmicewere
humanely euthanized based on Institutional Animal Care and Use Committee
(IACUC)-approved criteria. Mice were observed a minimum of 21 days after
exposure.
Mouse Challenge Study with SUDV
IFNabR/mice (4weeks old) (B6.129S2-Ifnar1tm1Agt/Mmjax) on theC57BL/6
background were purchased from Jackson Laboratories. Upon arrival, mice
were housed in microisolater cages and provided chow and water ad libitum.
Mice were challenged intraperitoneally with 1,000 PFU of SUDV and treated
at indicated times with antibodies by i.p. injection. Mice were observed daily
for lethality or clinical signs of disease. Moribund mice were humanely eutha-
nized based on IACUC-approved criteria.
Guinea Pig Challenge Studies
Female Hartley guinea pigs (4–6 weeks old, 250–300 g) were purchased from
Charles River Laboratories and randomly assigned into different groups. All
guinea pigs were challenged with an i.p. dose of 1,000 3 LD50 GPA-EBOV
(Volchkov et al., 2000) or 1,000 3 LD50 GPA-SUDV (Wong et al., 2015) in 1 ml
DMEM. The mAbs or mAb cocktail were given in an i.p. dose once at 1 or 3
dpi with 5 mg of each individual mAb or mAb cocktail (at a 1:1:1 ratio of each
mAb) per animal. The control groupwas given 1ml PBS. All animals weremoni-
tored for signs of disease, survival, and weight change for 15–16 days, and
survival was monitored for 12 additional days.
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